KALA BIO (KALA)
NASDAQ:KALA
Want to see KALA full AI Analyst Report?
KALA Stock Chart & Stats
$0.62
-$0.34(-4.42%)
At close: 4:00 PM EST
$0.62
-$0.34(-4.42%)
Day’s Range― - ―
52-Week Range$0.15 - $20.60
Previous CloseN/A
Volume15.45K
Average Volume (3M)1.94M
Market Cap
$181.17M
Enterprise Value-$3.20M
Total Cash (Recent Filing)$21.10M
Total Debt (Recent Filing)$31.05M
Price to Earnings (P/E)―
Beta1.84
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding911,330,200
10 Day Avg. Volume624,022
30 Day Avg. Volume1,940,241
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.65
Price to Sales (P/S)0.00
P/FCF Ratio-0.14
Enterprise Value/Market Cap-0.02
Enterprise Value/Revenue-12.59
Enterprise Value/Gross Profit399.66
Enterprise Value/Ebitda0.10
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.53
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Exclusive AI Platform LicenseThe exclusive Researgency license gives KALA a differentiated, on‑premises AI product for biotech customers. That creates a pathway to recurring platform revenues, addresses data‑sovereignty needs, and lets the company pivot from pure R&D risk to scalable service contracts over the medium term.
Commercial AI Product ReadinessReadiness to ship a commercial AI agent signals a structural shift to a dual‑engine model (drug pipeline plus commercial software). Delivering enterprise products enables recurring, higher‑margin revenue and customer relationships, reducing binary reliance on clinical outcomes for growth.
Debt EliminationEliminating debt materially reduces solvency and interest risks, improving financial flexibility to pursue partnerships or platform investments. Being debt‑free preserves strategic optionality and lowers the threshold for executing non‑debt growth initiatives despite a small asset base.
Bears Say
Zero Revenue And Cash BurnNo revenue combined with persistent negative operating and free cash flow is a core structural weakness. The company must repeatedly access external capital to fund operations, constraining runway and forcing financing that can dilute shareholders and limit long‑term strategic investment.
Fragile Balance Sheet / Small Asset BaseA sharply reduced asset base and compressed equity leave little internal capital to support clinical programs or scale an AI infrastructure business. The limited balance sheet increases dependency on external financings or partnerships, raising execution risk for both drug and platform initiatives.
Dilution And Listing Compliance ActionsRecent convertible preferred financings, authorization to expand share count and reverse‑split mechanics create a meaningful equity overhang and dilution risk. That structural dilution, paired with listing‑compliance actions, can impair shareholder value and complicate future capital access and incentive alignment.
KALA BIO News
KALA FAQ
What was KALA BIO’s price range in the past 12 months?
KALA BIO lowest stock price was $0.14 and its highest was $20.60 in the past 12 months.
What is KALA BIO’s market cap?
KALA BIO’s market cap is $181.17M.
When is KALA BIO’s upcoming earnings report date?
KALA BIO’s upcoming earnings report date is May 19, 2026 which is in 33 days.
How were KALA BIO’s earnings last quarter?
Currently, no data Available
Is KALA BIO overvalued?
According to Wall Street analysts KALA BIO’s price is currently Overvalued.
Does KALA BIO pay dividends?
KALA BIO does not currently pay dividends.
What is KALA BIO’s EPS estimate?
KALA BIO’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does KALA BIO have?
KALA BIO has 911,330,200 shares outstanding.
What happened to KALA BIO’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of KALA BIO?
Currently, no hedge funds are holding shares in KALA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
KALA BIO Stock Smart Score
Company Description
KALA BIO
Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.
Technical Analysis
Ownership Overview
0.08% Insiders
0.01% Mutual Funds
0.24% Other Institutional Investors
99.66% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---